Filing Details

Accession Number:
0001209191-17-037268
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-06-02 16:33:12
Reporting Period:
2017-06-01
Filing Date:
2017-06-02
Accepted Time:
2017-06-02 16:33:12
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1652923 Avexis Inc. AVXS Biological Products, (No Disgnostic Substances) (2836) 901038273
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1665124 Sukumar Nagendran C/O Avexis, Inc.
2275 Half Day Road, Suite 200
Bannockburn IL 60015
Sr. Vp & Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-06-01 1,780 $18.47 1,780 No 4 M Direct
Common Stock Disposition 2017-06-01 633 $70.20 1,147 No 4 S Direct
Common Stock Disposition 2017-06-01 977 $71.19 170 No 4 S Direct
Common Stock Disposition 2017-06-01 170 $71.91 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2017-06-01 1,780 $0.00 1,780 $18.47
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
194,514 2025-10-13 No 4 M Direct
Footnotes
  1. These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 2, 2016.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.59 to $70.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.66 to $71.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.69 to $72.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4.
  5. 49,963 shares vested and became exercisable on September 14, 2016; the remaining shares will vest and become exercisable in 36 equal monthly installments thereafter until September 14, 2019, subject to the Reporting Person's continuous service with the Issuer on each such date.